



FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 16991.017	APPLICATION NO. 10/785,109
		APPLICANTS Masaaki GOTO <i>et al.</i>	
		FILING DATE February 25, 2004	GROUP 1646

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
MPP	AA1	0 784 093 A1 ✓	07/1997	EPO			Yes No
↑	AB1	0 974 671 A1 ✓	01/2000	EPO			Yes No
	AC1	1 127 578 A1 ✓	08/2001	EPO			Yes No
	AD1	1 270 015 A2 ✓	01/2003	EPO			Yes No
	AE1	1 270 015 A3 ✓	02/2004	EPO			Yes No
	AF1	62-201825 ✓	09/1987	Japan		X (abstract only)	Yes No
	AG1	98/46211 A1 ✓	10/1998	PCT			Yes No
	AH1	98/46644 A1 ✓	10/1998	PCT		X (abstract only)	Yes No
	AI1	99/15691 A1 ✓	04/1999	PCT		X (abstract only)	Yes No
	AJ1	01/44472 A1 ✓	06/2001	PCT			Yes No
↓	AK1	03/002713 A2 ✓	01/2003	PCT			Yes No
MPP	AL1	03/074084 A1 ✓	09/2003	PCT			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MPP	AM1 ✓	Jean-Jacques Body, "Current and Future Directions in Medical Therapy: Hypercalcemia," <i>CANCER Supplement</i> , 88(12):3054-3058 (2000)
MPP	AN1 ✓	<i>Chemical Abstracts</i> , Vol. 123, No. 18, Abstract No. 237583p (1995)
MPP	AO1 ✓	Chowdhury <i>et al.</i> , "Effects of Heparin on Osteoclast Activity," <i>Journal of Bone and Mineral Research</i> , 7(7):771-777 (1992)

EXAMINER	DATE CONSIDERED
MICHAEL PAUL	10/16/06 3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	16991.017	10/785,109
	APPLICANTS	
	Masaaki GOTO <i>et al.</i>	
FILING DATE	GROUP	
February 25, 2004	1646	

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

WPP	AA2 /	Cochran and Abernathy, "Modulation of Bone Resorption by Glycosaminoglycans: Effects of Parathyroid Hormone and Interleukin-1," <i>Bone</i> , 9(5):331-335 (1988)
↑	AB2 /	Fautrel and Guillemin, "Cost of illness studies in rheumatic diseases," <i>Current Opinion in Rheumatology</i> , 14:121-126 (2002)
↓	AC2 /	Green <i>et al.</i> , "Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short-Term Rat Models," <i>Pharmacology & Toxicology</i> , 80:225-230 (1997)
	AD2 /	Iqbal and Sobhan, "Osteoporosis: A Review," <i>Missouri Medicine</i> , 99(1):19-24 (2002)
	AE2 /	Porcel <i>et al.</i> , "Anaphylaxis to calcitonin," <i>Allergologia et immunopathologia</i> , 28(4):243-245 (2000)
	AF2 /	Romas <i>et al.</i> , "Involvement of Receptor Activator of NF κ B Ligand and Tumor Necrosis Factor- α in Bone Destruction in Rheumatoid Arthritis," <i>Bone</i> , 30(2):340-346 (2002)
	AG2 /	Tomoyasu <i>et al.</i> , "Characterization of Monomeric and Homodimeric Forms of Osteoclastogenesis Inhibitory Factor," <i>Biochemical and Biophysical Research Communications</i> , 245(2):382-387 (1998)
↓	AH2 /	White and Schilling, "Postmenopausal Hormone Replacement: Historical Perspectives and Current Concerns," <i>Clinical Excellence for Nurse Practitioners</i> , 4(5):277-285 (2000)
WPP	AI2 /	Yamamoto <i>et al.</i> , "Hypocalcemic Effect of Osteoclastogenesis Inhibitory Factor/Osteoprotegerin in the Thyroparathyroidectomized Rat," <i>Endocrinology</i> , 139(9):4012-4015 (1998)
	AJ2	
	AK2	

EXAMINER	MICHAEL PHIL	DATE CONSIDERED
3-16-06		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		16991.017	10/785,109
		APPLICANTS	
		Masaaki GOTO <i>et al.</i>	
FILING DATE	GROUP		
February 25, 2004	1646		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
MDP	AA3	4,179,337	12/1979	Davis <i>et al.</i>			
↑	AB3	4,710,473	12/1987	Morris			
	AC3	4,959,314	09/1990	Mark <i>et al.</i>			
	AD3	5,118,667	06/1992	Adams <i>et al.</i>			
	AE3	5,366,859	11/1994	Miyoshi <i>et al.</i>			
	AF3	5,374,529	12/1994	Caterson <i>et al.</i>			
	AG3	5,393,739	02/1995	Bentz <i>et al.</i>			
	AH3	5,427,954	06/1995	Sandy <i>et al.</i>			
	AI3	5,447,851	09/1995	Beutler <i>et al.</i>			
	AJ3	5,457,035	10/1995	Baum <i>et al.</i>			
	AK3	5,545,722	08/1996	Naka			
	AL3	5,578,569	11/1996	Tam			
	AM3	5,585,479	12/1996	Hoke <i>et al.</i>			
	AN3	5,599,708	02/1997	Mundy <i>et al.</i>			
	AO3	5,658,756	08/1997	Rodan <i>et al.</i>			
	AP3	5,736,506	04/1998	Naka			
	AQ3	5,830,850	11/1998	Gelb <i>et al.</i>			
	AR3	5,843,678	12/1998	Boyle			
	AS3	5,843,901	12/1998	Roeske			
	AT3	5,985,832	11/1999	Roodman <i>et al.</i>			
↓	AU3	6,015,938	01/2000	Boyle <i>et al.</i>			
MDP	AV3	6,017,729	01/2000	Anderson <i>et al.</i>			

EXAMINER

MICHAEL plau

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		16991.017	10/785,109
		APPLICANTS	
		Masaaki GOTO <i>et al.</i>	
FILING DATE	GROUP		
February 25, 2004	1646		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
MOP	AA4	6,046,033	04/2000	Goto <i>et al.</i>			
↑	AB4	6,087,555	07/2000	Dunstan <i>et al.</i>			
	AC4	6,242,213 B1	06/2001	Anderson			
	AD4	6,242,586 B1	06/2001	Gorman <i>et al.</i>			
	AE4	6,271,349 B1	07/2001	Dougall <i>et al.</i>			
	AF4	6,284,485 B1	09/2001	Boyle <i>et al.</i>			
	AG4	6,284,728 B1	09/2001	Boyle <i>et al.</i>			
	AH4	6,284,740 B1	09/2001	Boyle <i>et al.</i>			
	AI4	6,288,032 B1	09/2001	Boyle <i>et al.</i>			
	AJ4	6,297,022 B1	10/2001	McDonnell <i>et al.</i>			
	AK4	6,316,408 B1	11/2001	Boyle			
	AL4	6,369,027 B1	04/2002	Boyle <i>et al.</i>			
	AM4	6,419,929 B1	07/2002	Anderson			
	AN4	6,479,635 B1	11/2002	Anderson <i>et al.</i>			
	AO4	6,525,180 B1	02/2003	Gorman <i>et al.</i>			
	AP4	6,528,482 B1	03/2003	Anderson <i>et al.</i>			
	AQ4	6,537,763 B1	03/2003	Dougall <i>et al.</i>			
	AR4	6,562,948 B2	05/2003	Anderson			
	AS4	6,613,544 B1	09/2003	Boyle <i>et al.</i>			
	AT4	6,649,164 B2	11/2003	Maraskovsky			
↓	AU4	6,693,175 B2	02/2004	Yano <i>et al.</i>			
MOP	AV4	6,740,522 B2	05/2004	Anderson			

EXAMINER

MICHAEL DAN

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		16991.017	10/785,109
		APPLICANTS	
		Masaaki GOTO <i>et al.</i>	
FILING DATE	GROUP		
February 25, 2004	1646		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
WDP	AA5	2002/0081720 A1	06/2002	Dougall <i>et al.</i>			
↑	AB5	2002/0086826 A1	07/2002	Anderson <i>et al.</i>			
	AC5	2002/0086827 A1	07/2002	Anderson <i>et al.</i>			
	AD5	2002/0127637 A1	09/2002	Jian <i>et al.</i>			
	AE5	2002/0150989 A1	10/2002	Greene <i>et al.</i>			
	AF5	2002/0169117 A1	11/2002	Maraskovsky			
	AG5	2003/0045456 A1	03/2003	Yamamoto <i>et al.</i>			
	AH5	2003/0100069 A1	05/2003	Jian <i>et al.</i>			
	AI5	2003/0100488 A1	05/2003	Boyle			
	AJ5	2003/0103978 A1	06/2003	Deshpande <i>et al.</i>			
	AK5	2003/0104485 A1	06/2004	Boyle			
	AL5	2003/0139325 A1	07/2003	Yamamoto <i>et al.</i>			
	AM5	2003/0144480 A1	07/2003	Gorman <i>et al.</i>			
	AN5	2003/0166097 A1	09/2003	Greene <i>et al.</i>			
	AO5	2003/0175840 A1	09/2003	Anderson <i>et al.</i>			
	AP5	2003/0176647 A1	09/2003	Yamaguchi <i>et al.</i>			
	AQ5	2003/0181418 A1	09/2003	Kumakura <i>et al.</i>			
	AR5	2003/0207827 A1	11/2003	Boyle <i>et al.</i>			
	AS5	2003/0208045 A1	11/2003	Yamaguchi <i>et al.</i>			
↓	AT5	2003/0216297 A1	11/2003	Kumakura <i>et al.</i>			
WDP	AUS	2004/0033535 A1	02/2004	Boyle <i>et al.</i>			

EXAMINER

MICHAEL PARK

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO.	APPLICATION NO.		
			16991.017	10/785,109		
			APPLICANTS			
			Masaaki GOTO <i>et al.</i>			
FILING DATE	GROUP					
February 25, 2004	1646					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
MDP	AA6	0514130 A2	11/1992	EPO			Yes No
↑	AB6	0514130 A3	11/1992	EPO			Yes No
	AC6	0526905 A2	02/1993	EPO			Yes No
	AD6	0526905 A3	02/1993	EPO			Yes No
	AE6	0727211 A1	08/1996	EPO			Yes No
	AF6	0874045 A1	10/1998	EPO			Yes No
	AG6	0911342 A1	04/1999	EPO			Yes No
	AH6	330400	05/1999	New Zealand			Yes No
	AI6	86/00922 A1	02/1986	PCT			Yes No
	AJ6	90/14363 A1	11/1990	PCT			Yes No
	AK6	93/12227 A1	06/1993	PCT			Yes No
	AL6	93/21946 A1	11/1993	PCT			Yes No
	AM6	95/11308 A1	04/1995	PCT			Yes No
	AN6	96/28546 A1	09/1996	PCT			Yes No
	AO6	97/00317 A1	01/1997	PCT			Yes No
	AP6	97/00318 A1	01/1997	PCT			Yes No
	AQ6	97/23614 A1	07/1997	PCT			Yes No
	AR6	98/07840 A1	02/1998	PCT			Abstract X Yes only No
	AS6	98/25958 A2	06/1998	PCT			Yes No
↓	AT6	98/28424 A2	07/1998	PCT			Yes No
MDP	AU6	98/28426 A2	07/1998	PCT			Yes No

EXAMINER

MICHAEL PAUL

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO..	APPLICATION NO.		
			16991.017	10/785,109		
			APPLICANTS			
			Masaaki GOTO <i>et al.</i>			
FILING DATE	GROUP					
February 25, 2004	1646					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
MDP	AA7	98/46751 A1	10/1998	PCT			Yes No
↑	AB7	98/49305 A1	11/1998	PCT			Yes No
	AC7	99/19468 A1	04/1999	PCT			Yes No
	AD7	99/53942 A1	10/1999	PCT			Yes No
	AE7	99/58674 A2	11/1999	PCT			Yes No
	AF7	99/58674 A3	11/1999	PCT			Yes No
	AG7	01/03719 A2	01/2001	PCT			Yes No
	AH7	01/03719 A3	01/2001	PCT			Yes No
	AI7	01/17543 A2	03/2001	PCT			Yes No
↓	AJ7	01/17543 A3	03/2001	PCT			Yes No
MPP	AK7	01/18203 A1	03/2001	PCT			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MDP	AL	7	Adams <i>et al.</i> , "Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project", <i>Science</i> , 252:1651-1656 (1991)
↑	AM	7	Anderson <i>et al.</i> , "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", <i>Nature</i> , 390:175-179 (1997)
	AN	7	Banks <i>et al.</i> , "Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease?", <i>European Journal of Clinical Investigation</i> , 24(12):813-817 (1994)
	AO	7	Banner <i>et al.</i> , "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation", <i>Cell</i> , 73(3):431-445 (1993)
↓	AP	7	Bennett, C. F., "Antisense Research", <i>Science</i> , 271:434 (1996)
MDP	AQ	7	Beutler and Cerami, "Tumor Necrosis, Cachexia, Shock, and Inflammation: a Common Mediator", <i>Annual Review of Biochemistry</i> , 57:505-518 (1988)

EXAMINER	MICHAEL Apk	DATE CONSIDERED
3-16-06		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

			ATTY. DOCKET NO. 16991.017	APPLICATION NO. 10/785,109
FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			APPLICANTS Masaaki GOTO <i>et al.</i>	
			FILING DATE February 25, 2004	GROUP 1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MPP	AA	8	Beutler and van Huffel, "Unraveling Function in the TNF Ligand and Receptor Families", <i>Science</i> , 264:667-668 (1994)
↑	AB	8	Boyce <i>et al.</i> , "Effects of Interleukin-1 on Bone Turnover in Normal Mice", <i>Endocrinology</i> , 125(3):1142-1150 (1989)
	AC	8	Bradley and Robertson, "Embryo-Derived Stem Cells: a Tool for Elucidating the Developmental Genetics of the Mouse", <i>Current Topics in Developmental Biology</i> , 20:357-371 (1986)
	AD	8	Brinster <i>et al.</i> , "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs", <i>Proceedings of the National Academy of Sciences of USA</i> , 82:4438-4442 (1985)
	AE	8	Bucay <i>et al.</i> , "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", <i>Genes and Development</i> , 12(9):1260-1268 (1998)
	AF	8	Capon <i>et al.</i> , "Designing CD4 immunoadhesins for AIDS therapy", <i>Nature</i> , 337(6207):525-531 (1989)
	AG	8	Cappuccini, M. R., "Altering the Genome by Homologous Recombination", <i>Science</i> , 244:1288-1292 (1989)
	AH	8	Chambers <i>et al.</i> , "Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2K ^b IsA58 transgenic mouse", <i>Proceedings of the National Academy of Sciences of USA</i> , 90:5578-5582 (1993)
	AI	8	Charreau <i>et al.</i> , "Transgenesis in rats: technical aspects and models", <i>Transgenic Research</i> , 5(4):223-234 (1996)
	AJ	8	Chen <i>et al.</i> , "Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor- α to Its Two Receptors", <i>Journal of Biological Chemistry</i> , 270(6):2874-2878 (1995)
	AK	8	Chenu <i>et al.</i> , "Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cells", <i>Proceedings of the National Academy of Sciences of USA</i> , 85(15):5683-5687 (1988)
↓	AL	8	Chomczynski and Sacchi, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", <i>Analytical Biochemistry</i> , 162(1):156-159 (1987)
MPP	AM	8	Culver and Blaese, "Gene therapy for cancer", <i>Trends in Genetics</i> , 10(5):174-178 (1994)

EXAMINER

MICHAEL PIAN

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
			FILING DATE	GROUP
			February 25, 2004	1646

MOP	AA	9	Database EMEST16, EMBL Database Accession No. AA170348 <i>no date</i>	
↑	AB	9	Database GenEMBL, EMBL Accession No. AF019048 <i>no date</i>	
	AC	9	Database EMROD, EMBL Database Accession No. M59378 <i>no date</i>	
	AD	9	DeClerck <i>et al.</i> , "Inhibition of Autoproteolytic Activation of Interstitial Procollagenase by Recombinant Metalloproteinase Inhibitor MI/TIMP-2", <i>Journal of Biological Chemistry</i> , 266(6):3893-3899 (1991)	
	AE	9	Demer, L. L., "A Skeleton in the Atherosclerosis Closet", <i>Circulation</i> , 92(8):2029-2032 (1995)	
	AF	9	Ebi <i>et al.</i> , "Mechanism of Mast Cell Deficiency in Mutant Mice of mi/mi Genotype: An Analysis by Co-Culture of Mast Cells and Fibroblasts", <i>Blood</i> , 75(6):1247-1251 (1990)	
	AG	9	Efrat, S., "Prospects for gene therapy of insulin-dependent diabetes mellitus", <i>Diabetologia</i> , 41(12):1401-1409 (1998)	
	AH	9	Ellison <i>et al.</i> , "The nucleotide sequence of a human immunoglobulin C _y 1 gene", <i>Nucleic Acids Research</i> , 10(13):4071-4079 (1982)	
	AI	9	Engels and Uhlmann, "Gene Synthesis", <i>Angew. Chem. Int. Ed. Engl.</i> , 28:716-734 (1989)	
	AJ	9	Fawthrop <i>et al.</i> , "The Effect of Transforming Growth Factor β on the Plasminogen Activator Activity of Normal Human Osteoblast-like Cells and a Human Osteosarcoma Cell Line MG-63", <i>Journal of Bone and Mineral Research</i> , 7(12):1363-1371 (1992)	
	AK	9	Fenton <i>et al.</i> , "Long-Term Culture of Disaggregated Rat Osteoclasts: Inhibition of Bone Resorption and Reduction of Osteoclast-Like Cell Number by Calcitonin and PTHrP[107-139]", <i>Journal of Cellular Physiology</i> , 155:1-7 (1993)	
	AL	9	Fisher <i>et al.</i> , "Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome", <i>Cell</i> , 81(6):935-946 (1995)	
↓	AM	9	Galli-Taliadoros <i>et al.</i> , "Gene knock-out technology: a methodological overview for the interested novice", <i>Journal of Immunological Methods</i> , 181(1):1-15 (1995)	
MOP	AN	9	George <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis", <i>Macromolecular Sequencing and Synthesis Selected Methods and Applications</i> , pp. 127-149 (1988)	

EXAMINER	MICHAEL PPA	DATE CONSIDERED
3-16-06		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
			FILING DATE	GROUP
			February 25, 2004	1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>MOP</i>	AA	10	Goeddel, D. V., "Systems for Heterologous Gene Expression", <i>Methods in Enzymology</i> , 185:3-7 (1990)
<i>↑</i>	AB	10	Goeddel <i>et al.</i> , "Tumor Necrosis Factors: Gene Structure and Biological Activities", <i>Cold Spring Harbor Symposia on Quantitative Biology, Volume LI</i> , pp. 597-609 (1986)
<i>↑</i>	AC	10	Goodwin <i>et al.</i> , "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor", <i>Molecular and Cellular Biology</i> , 11(6):3020-3026 (1991)
<i>↑</i>	AD	10	Gowen <i>et al.</i> , "Preferential Inhibition of Cytokine-Stimulated Bone Resorption by Recombinant Interferon Gamma", <i>Journal of Bone and Mineral Research</i> , 1(5):469-474 (1986)
	AE	10	Graves and Jilka, "Comparison of Bone and Parathyroid Hormone as Stimulators of Osteoclast Development and Activity in Calvarial Cell Cultures From Normal and Osteopetrotic (mi/mi) Mice", <i>Journal of Cellular Physiology</i> , 145(1):102-109 (1990)
	AF	10	Gribskov <i>et al.</i> , "Profile analysis: Detection of distantly related proteins", <i>Proceedings of the National Academy of Sciences of USA</i> , 84(13):4355-4358 (1987)
	AG	10	Grigoriadis <i>et al.</i> , "c-Fos: A Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling", <i>Science</i> , 266:443-448 (1994)
	AH	10	Hattersley <i>et al.</i> , "Human Macrophage Colony-Stimulating Factor Inhibits Bone Resorption by Osteoclasts Disaggregated From Rat Bone", <i>Journal of Cellular Physiology</i> , 137(1):199-203 (1988)
	AI	10	Hodgson <i>et al.</i> , "Advances in vector systems for gene therapy", <i>Exp. Opin. Ther. Patents</i> , 5(5):459-468 (1995)
	AJ	10	International Search Report, International Application No. PCT/JP96/00374 (1996)
	AK	10	International Search Report, International Application No. PCT/JP98/01728 (1998)
	AL	10	Isozaki <i>et al.</i> , "Cell Type-Specific Deficiency of c-kit Gene Expression in Mutant Mice of mi/mi Genotype", <i>American Journal of Pathology</i> , 145(4):827-836 (1994)
<i>↓</i>	AM	10	Jimi <i>et al.</i> , "Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact", <i>Endocrinology</i> , 137(5):2187-2190 (1996)
<i>MOP</i>	AN	10	Johnson <i>et al.</i> , "Pleiotropic Effects of a Null Mutation in the c-fos Proto-Oncogene", <i>Cell</i> , 71(4):577-586 (1992)

EXAMINER

michael plan

DATE CONSIDERED

3/16/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
			FILING DATE	GROUP
			February 25, 2004	1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MOP	AA	11	Kaji <i>et al.</i> , "Insulin-Like Growth Factor-I Mediates Osteoclast-Like Cell Formation Stimulated by Parathyroid Hormone", <i>Journal of Cellular Physiology</i> , 172(1):55-62 (1997)
↑	AB	11	Karaplis, A. C., "Gene Targeting", <i>Principles of Bone Biology</i> , pp. 1189-1201, Academic Press (1996)
	AC	11	Kasono <i>et al.</i> , "Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture", <i>Bone and Mineral</i> , 21(3):179-188 (1993)
	AD	11	Kohno <i>et al.</i> , "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor", <i>Proceedings of the National Academy of Sciences of USA</i> , 87(21):8331-8335 (1990)
	AE	11	Kraulis, P. J., "MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures", <i>Journal of Applied Crystallography</i> , 24(5):946-950 (1991)
	AF	11	Kukita <i>et al.</i> , "Osteoinductive factor inhibits formation of human osteoclast-like cells", <i>Proceedings of the National Academy of Sciences of USA</i> , 87:3023-3026 (1990)
	AG	11	Lacey <i>et al.</i> , "Interleukin 4, Interferon-γ, and Prostaglandin E Impact the Osteoclastic Cell-Forming Potential of Murine Bone Marrow Macrophages", <i>Endocrinology</i> , 136(6):2367-2376 (1995)
	AH	11	Levine and Williams, "Automated measurement of mouse apolipoprotein B: convenient screening tool for mouse models of atherosclerosis", <i>Clinical Chemistry</i> , 43(4):669-674 (1997)
	AI	11	Lewis <i>et al.</i> , "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific", <i>Proceedings of the National Academy of Sciences of USA</i> , 88:2830-2834 (1991)
	AJ	11	Loetscher <i>et al.</i> , "Tumor Necrosis Factor: Receptors and Inhibitors", <i>Cancer Cells</i> , 3(6):221-226 (1991)
	AK	11	Lowe <i>et al.</i> , "Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts" <i>Proceedings of the National Academy of Sciences of USA</i> , 90(10):4485-4489 (1993)
↓	AL	11	Lüthy <i>et al.</i> , "Improving the sensitivity of the sequence profile method", <i>Protein Science</i> , 3(1):139-146 (1994)
MOP	AM	11	MacDonald <i>et al.</i> , "Isolation of RNA Using Guanidinium Salts", <i>Methods in Enzymology</i> , 152:219-227 (1987)

EXAMINER

Michael Doh

DATE CONSIDERED

3-26-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
			FILING DATE	GROUP
			February 25, 2004	1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MDP	AA	12	Maitland and McDougal, "Biochemical Transformation of Mouse Cells by Fragments of Herpes Simplex Virus DNA", <i>Cell</i> , 11(1):233-241 (1977)
↑	AB	12	Marks, Jr., and Lane, "Osteopetrosis, a New Recessive Skeletal Mutation on Chromosome 12 of the Mouse", <i>Journal of Heredity</i> , 67(1):11-18 (1976)
	AC	12	Marshall, E., "Gene Therapy's Growing Pains", <i>Science</i> , 269:1050-1055 (1995)
	AD	12	Martin <i>et al.</i> , "Interleukins in the Control of Oosteoclast Differentiation", <i>Critical Reviews™ in Eukaryotic Gene Expression</i> , 8(2):107-23 (1998)
	AE	12	Matsudaira, P., "Sequence from Picomole Quantities of Proteins Electrophoresed onto Polyvinylidene Difluoride Membranes", <i>Journal of Biological Chemistry</i> , 262(21):10035-10038 (1987)
	AF	12	Miller and Vile, "Targeted vectors for gene therapy", <i>FASEB Journal</i> , 9(2):190-199 (1995)
	AG	12	Miller and Vile, "Gene Transfer and Antisense Nucleic Acid Techniques", <i>Parasitology Today</i> , 10(3):92-97 (1994)
	AH	12	Milligan <i>et al.</i> , "Current Concepts in Antisense Drug Design", <i>Journal of Medicinal Chemistry</i> , 36(14):1923-1937 (1993)
	AI	12	Mizuno <i>et al.</i> , "Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin", <i>Biochemical and Biophysical Research Communications</i> , 247(3):610-615 (1998)
	AJ	12	Montgomery <i>et al.</i> , "Herpes Simplex Virus-I Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family", <i>Cell</i> , 87(3):427-436 (1996)
	AK	12	Morony <i>et al.</i> , "A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL-1 β , TNF- α , PTH, PTHrP, and 1,25(OH) ₂ D ₃ ", <i>Journal of Bone and Mineral Research</i> , 14(9):1478-1485 (1999)
↓	AL	12	Mundy <i>et al.</i> , "The Effects of Cytokines and Growth Factors on Osteoblastic Cells", <i>Bone</i> , 17(2 Suppl):71S-75S (1995)
MDP	AM	12	Nagata and Golstein, "The Fas Death Factor", <i>Science</i> , 267:1449-1456 (1995)

EXAMINER	<u>MICHAEL SPARKS</u>	DATE CONSIDERED
<i>3-16-06</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
			FILING DATE	GROUP
			February 25, 2004	1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MPP	AA	13	Ogden and Adams, "Electrophoresis in Agarose and Acrylamide Gels", <i>Methods in Enzymology</i> , 152:61-87 (1987)
↑	AB	13	Parhami and Demer, "Arterial calcification in face of osteoporosis in ageing: can we blame oxidized lipids", <i>Current Opinion in Lipidology</i> , 8(5):312-314 (1997)
	AC	13	Pearson, W. R., "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", <i>Methods in Enzymology</i> , 183:63-98 (1990)
	AD	13	Perigaud <i>et al.</i> , "Nucleoside analogues as chemotherapeutic agents: a review", <i>Nucleosides & Nucleotides</i> , 11(2-4):903-945 (1992)
	AE	13	Reddi, A. H., "Bone Morphogenesis and Modeling: Soluble Signals Sculpt Osteosomes in the Solid State", <i>Cell</i> , 89:159-161 (1997)
	AF	13	Rieger <i>et al.</i> , <i>Glossary of Genetics and Cytogenetics</i> , p. 17, Springer-Verlag, Berlin Heidlberg, New York (1976)
	AG	13	Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting", <i>Advanced Drug Delivery Reviews</i> , 18:115-131 (1996)
	AH	13	Roodman, G. D., "Role of Cytokines in the Regulation of Bone Resorption", <i>Calcified Tissue International</i> , 53(Suppl. 1):S94-S98 (1993)
	AI	13	Rosati <i>et al.</i> , "Normal long bone growth and development in type X collagen-null mice", <i>Nature Genetics</i> , 8(2):129-135 (1994)
	AJ	13	Schinke <i>et al.</i> , "Molecular determinants of arterial calcification", <i>Annals of Medicine</i> , 30(6):538-541 (1998)
	AK	13	Shahinian <i>et al.</i> , "Differential T Cell Costimulatory Requirements in CD28-Deficient Mice", <i>Science</i> , 261:609-612 (1993)
↓	AL	13	Siddhanti <i>et al.</i> , "Molecular to Pharmacologic Control of Osteoblast Proliferation and Differentiation", <i>Journal of Cellular Biochemistry</i> , 55(3):310-320 (1994)
MPP	AM	13	Simonet <i>et al.</i> , "Long-term Impaired Neutrophil Migration in Mice Overexpressing Human Interleukin-8", <i>Journal of Clinical Investigation</i> , 94(3):1310-1319 (1994)

EXAMINER	<i>Michael P.M.</i>	DATE CONSIDERED
3-16-06		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
			FILING DATE	GROUP
			February 25, 2004	1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>MOP</i>	AA	14	Simonet <i>et al.</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", <i>Cell</i> , 89:309-319 (1997)
<i>↑</i>	AB	14	Smith <i>et al.</i> , "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death", <i>Cell</i> , 76:959-962 (1994)
	AC	14	Soriano <i>et al.</i> , "Targeted Disruption of the c-src Proto-Oncogene Leads to Osteopetrosis in Mice", <i>Cell</i> , 64(4):693-702 (1991)
	AD	14	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?", <i>Science</i> , 261:1004-1012 (1993)
	AE	14	Stull and Szoka, Jr., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", <i>Pharmaceutical Research</i> , 12(4):465-483 (1995)
	AF	14	Suda <i>et al.</i> , "Modulation of Osteoclast Differentiation by Local Factors", <i>Bone</i> , 17(2 Suppl):87S-91S (1995)
	AG	14	Suda <i>et al.</i> , "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family", <i>Cell</i> , 75(6):1169-1178 (1993)
	AH	14	Takada <i>et al.</i> , "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", <i>Bone and Mineral</i> , 17:347-359 (1992)
	AI	14	Tsuda <i>et al.</i> , "Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis", <i>Biochemical and Biophysical Research Communications</i> , 234(1):137-142 (1997)
	AJ	14	Udagawa <i>et al.</i> , "The Bone Marrow-Derived Stromal Cell Lines MC3T3-G2/PA6 and ST2 Support Osteoclast-Like Cell Differentiation in Cocultures with Mouse Spleen Cells", <i>Endocrinology</i> , 125(3):1805-1813 (1989)
	AK	14	Udagawa <i>et al.</i> , "Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells", <i>Proceedings of the National Academy of Sciences of USA</i> , 87(18):7260-7264 (1990)
<i>↓</i>	AL	14	Wagner, R. W., "Gene inhibition using antisense oligodeoxynucleotides", <i>Nature</i> , 372(6504):333-335 (1994)
<i>MOP</i>	AM	14	Wang, "Bone and haematopoietic defects in mice lacking c-fos", <i>Nature</i> , 360(6406):741-745 (1992)

EXAMINER

MICHAEL VNL

DATE CONSIDERED

3-16-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO.	APPLICATION NO.
			16991.017	10/785,109
			APPLICANTS	
			Masaaki GOTO <i>et al.</i>	
FILING DATE	GROUP			
February 25, 2004	1646			

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MDP	AA	15	Watanabe <i>et al.</i> , "Interleukin-4 as a Potent Inhibitor of Bone Resorption", <i>Biochemical and Biophysical Research Communications</i> , 172(3):1035-1041 (1990)
↑	AB	15	Westermann <i>et al.</i> , "Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides" <i>Biomedica Biochimica Acta</i> , 48(1):85-93 (1989)
	AC	15	Wiktor-Jedrzejczak <i>et al.</i> , "Hematological Characterization of Congenital Osteopetrosis in op/op Mouse (Possible Mechanism for Abnormal Macrophage Differentiation)", <i>Journal of Experimental Medicine</i> , 156(5):1516-1527 (1982)
	AD	15	Wiktor-Jedrzejczak <i>et al.</i> , "Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse", <i>Proceedings of the National Academy of Sciences of USA</i> , 87(12):4828-4832 (1990)
	AE	15	Wiley <i>et al.</i> , "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis", <i>Immunity</i> , 3(6):673-682 (1995)
	AF	15	Wong <i>et al.</i> , "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells", <i>Journal of Biological Chemistry</i> , 272(40):25190-25194 (1997)
	AG	15	Wu-Pong, S., "Oligonucleotides: Opportunities for Drug Therapy and Research", <i>Pharmaceutical Technology</i> , 118:102-114 (1994)
	AH	15	Yamaguchi <i>et al.</i> , "Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor", <i>Journal of Biological Chemistry</i> , 273(9):5117-5123 (1998)
	AI	15	Yan and Chao, "Disruption of Cysteine-rich Repeats of the p75 Nerve Growth Factor Receptor Leads to Loss of Ligand Binding", <i>Journal of Biological Chemistry</i> , 266(18):12099-12104 (1991)
	AJ	15	Yang <i>et al.</i> , "Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy", <i>Cancer Research</i> , 59(6):1236-1243 (1999)
↓	AK	15	Yasuda <i>et al.</i> , "Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL", <i>Proceedings of the National Academy of Sciences of USA</i> , 95(7):3597-3602 (1998)
↓	AL	15	Yoneda <i>et al.</i> , "Sumarin Suppresses Hypercalcemia and Osteoclastic Bone Resorption in Nude Mice Bearing a Human Squamous Cancer", <i>Cancer Research</i> , 55:1989-1993 (1995)
MDP	AM	15	Yoshida <i>et al.</i> , "The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene", <i>Nature</i> , 345(6274):442-444 (1990)

EXAMINER

MICHAEL PHIL

DATE CONSIDERED

3-16-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.